Monoclonal antibodies and Antibody-drug conjugates are important therapeutics in the field of oncology. The market for these biologics is becoming increasingly competitive as companies continue to innovate and develop new molecules for existing disease targets with greater efficacy. Furthermore, developers of biosimilars are hoping to steal market share from licenced products. To be successful firms must have manufacturing assets that allow flexibility, speed to market and facilitate process transfers without adding unnecessary operational complexity.
End-to-end processing solutions for MAbs and ADCs help improve a company’s competitiveness by reducing risks associated with uncertainties in manufacturing process development and scale-up. Knowledge from previous projects is leveraged to design flexibility into production assets while minimizing regulatory risks and allowing enhanced process understanding.
Establishing these production platforms requires companies to consider their overall objectives and use the right tools during early stage process development. This includes selecting the right partners for process development, applying the appropriate laboratory-scale technologies and using process-modelling tools to predict commercial-scale performance and costs.
Register for our webinar to learn how to approach process development to deliver standardized end-to-end bioprocess platforms for MAbs or ADCs that meet your requirements for quality, speed-to-market, scalability and performance.
Ian Schwartz
Process Development Consultant
Ian Schwartz recently joined Sartorius Stedim Biotech as a Process Development Consultant. Ian has over 12 years of experience in the biotechnology industry and specializes in anybody-drug conjugates (ADCs) and downstream protein purification processes.
He began his career at Biogen Idec and then moved to ImmunoGen where he became fluent in ADC process development, technology transfer and manufacturing operations. Ian then worked for MedImmune where he managed a manufacturing operations team. Most recently, he worked for Agensys (affiliate of Astellas Pharma) where he started up and managed the ADC process development group, technology transfer, and manufacturing support for a number of years.
With more than 12 years in the biotechnology industry, Ian supports, in his current role, process development and scale up of biological processes for Sartorius customers
Christophe Grimm
Antibodies Platform Marketing Manager
Christophe is currently Platform Manager at Sartorius Stedim Biotech and a specialist in supporting process optimisation activities. He has held various international sales,technical and marketing positions in the past 16 years at Sartorius Stedim Biotech. He has previously worked at Baxter Biosciences for 5 years; first as project engineer on the implementation of pharmaceutical line, then project leader in charge of the design, installation and validation of bulk line for recombinant protein production.
With more than 20 years of experience in biotech/pharma, he supports, in his current role, the integration of process platform approaches within the Sartorius portfolio to bring innovative and state-of-the-art solutions to the biopharmaceutical industry.
Christophe completed his studies with Master in Business administration.
- Understand the concept of standardized end-to-end platforms for MAbs & ADCs
- Learn how platforms deliver much more than simple yield optimization
- Learn how to apply early stage tools for platform development
- Learn which competencies are required for platform implementation
- Process Development Team Leaders
- Process Development Managers
- Process Development Scientists or Engineers
- Directors of Process Sciences
